Head to Head Analysis: HUTCHMED (NASDAQ:HCM) vs. Structure Therapeutics (NASDAQ:GPCR)

Structure Therapeutics (NASDAQ:GPCR) and HUTCHMED (NASDAQ:HCM) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Risk and Volatility

Structure Therapeutics has a beta of -1.43, indicating that its share price is 243% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.

Valuation & Earnings

This table compares Structure Therapeutics and HUTCHMED”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20 million	($1.00)	-54.51
HUTCHMED	$548.51 million	3.88	$456.91 million	N/A	N/A

HUTCHMED has higher revenue and earnings than Structure Therapeutics.

Profitability

This table compares Structure Therapeutics and HUTCHMED’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
HUTCHMED	N/A	N/A	N/A

Insider & Institutional Ownership

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Structure Therapeutics and HUTCHMED, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2	1	12	3	2.89
HUTCHMED	2	2	1	1	2.17

Structure Therapeutics presently has a consensus price target of $110.91, suggesting a potential upside of 103.47%. HUTCHMED has a consensus price target of $14.87, suggesting a potential upside of 21.86%. Given Structure Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Structure Therapeutics is more favorable than HUTCHMED.

Summary

Structure Therapeutics beats HUTCHMED on 6 of the 11 factors compared between the two stocks.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.